Literature DB >> 6429693

Absolute bioavailability of imipramine: influence of food.

D R Abernethyl, M Divoll, D J Greenblatt, J S Harmatz, R I Shader.   

Abstract

Imipramine hydrochloride (IMI) was administered to 12 healthy volunteers on three occasions in random sequence: 12.5 mg IV, 50 mg orally after overnight fast, and 50 mg orally 30 min after eating a standardized breakfast. IMI concentrations were measured by gas-liquid chromatography using nitrogen-phosphorous detection and pharmacokinetic and bioavailability parameters determined by iterative nonlinear least-squares regression analysis. After IV administration, mean kinetic variables were: volume of distribution, 21.0 l/kg; total clearance, 12.8 ml/min per kg, and elimination half-life, 21. h. Mean absolute bioavailability of IMI in the fasting state was 43.6%. When IMI was administered immediately after the standardized meal, absolute bioavailability was 44.1%. After oral administration, the time to peak IMI level was not changed by concurrent food ingestion (2.8 vs 3.2 h after dosage), and the peak IMI concentration was no different (35 vs 30 ng/ml). Thus concurrent food ingestion has no effect on IMI absolute bioavailability, peak concentration attained after oral dosage, or the time to peak concentration.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6429693     DOI: 10.1007/bf00427432

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  20 in total

1.  The treatment of depressive states with G 22355 (imipramine hydrochloride).

Authors:  R KUHN
Journal:  Am J Psychiatry       Date:  1958-11       Impact factor: 18.112

2.  Enhancement of the bioavailability of propranolol and metoprolol by food.

Authors:  A Melander; K Danielson; B Scherstén; E Wåhlin
Journal:  Clin Pharmacol Ther       Date:  1977-07       Impact factor: 6.875

3.  Binding of tricyclic antidepressants and perazine to human plasma. Methodology and findings in normals.

Authors:  M Brinkschulte; U Breyer-Pfaff
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1979-07       Impact factor: 3.000

4.  Effect of food on hepatic blood flow: implications in the "food effect" phenomenon.

Authors:  C K Svensson; D J Edwards; P M Mauriello; S H Barde; A C Foster; R A Lanc; E Middleton; D Lalka
Journal:  Clin Pharmacol Ther       Date:  1983-09       Impact factor: 6.875

Review 5.  Clinical pharmacology of slow channel blocking agents.

Authors:  R G McAllister
Journal:  Prog Cardiovasc Dis       Date:  1982 Sep-Oct       Impact factor: 8.194

6.  Reduced levels of tricyclic antidepressants in plasma from Vacutainers.

Authors:  D J Brunswick; J Mendels
Journal:  Commun Psychopharmacol       Date:  1977

7.  Pharmacokinetics of paracetamol (acetaminophen) after intravenous and oral administration.

Authors:  M D Rawlins; D B Henderson; A R Hijab
Journal:  Eur J Clin Pharmacol       Date:  1977-04-20       Impact factor: 2.953

8.  First-pass metabolism of imipramine in man.

Authors:  L F Gram; J Christiansen
Journal:  Clin Pharmacol Ther       Date:  1975-05       Impact factor: 6.875

9.  Physiological disposition of verapamil in man.

Authors:  M Schomerus; B Spiegelhalder; B Stieren; M Eichelbaum
Journal:  Cardiovasc Res       Date:  1976-09       Impact factor: 10.787

10.  Tricyclic antidepressant determination in human plasma by gas-liquid chromatography using nitrogen-phosphorous detection: application to single-dose pharmacokinetic studies.

Authors:  D R Abernethy; D J Greenblatt; R I Shader
Journal:  Pharmacology       Date:  1981       Impact factor: 2.547

View more
  7 in total

1.  [Expanding therapeutic reference ranges using dose-related reference ranges].

Authors:  E Haen; C Greiner; W Bader; M Wittmann
Journal:  Nervenarzt       Date:  2008-05       Impact factor: 1.214

Review 2.  Pharmacokinetic optimisation of tricyclic antidepressant therapy.

Authors:  M Furlanut; P Benetello; E Spina
Journal:  Clin Pharmacokinet       Date:  1993-04       Impact factor: 6.447

Review 3.  Clinical pharmacokinetics of imipramine and desipramine.

Authors:  F R Sallee; B G Pollock
Journal:  Clin Pharmacokinet       Date:  1990-05       Impact factor: 6.447

Review 4.  Pharmacokinetic changes of psychotropic drugs in patients with liver disease: implications for dose adaptation.

Authors:  Chantal Schlatter; Sabin S Egger; Lydia Tchambaz; Stephan Krähenbühl
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

Review 5.  Clinical pharmacokinetics of drugs used to treat urge incontinence.

Authors:  David R P Guay
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 6.  Pharmacokinetic optimisation of therapy with newer antidepressants.

Authors:  P J Goodnick
Journal:  Clin Pharmacokinet       Date:  1994-10       Impact factor: 6.447

7.  Prediction of Metabolite-to-Parent Drug Exposure: Derivation and Application of a Mechanistic Static Model.

Authors:  Ernesto Callegari; Manthena V S Varma; R Scott Obach
Journal:  Clin Transl Sci       Date:  2020-02-04       Impact factor: 4.689

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.